What is known and objective: Posaconazole is an extendedspectrum triazole antifungal with activity against a variety of clinically significant yeasts and moulds. Posaconazole is not currently approved by the U.S. Food and Drug Administration for use in children younger than 13 years of age. Our primary objective was to describe the dosing and observed trough concentrations with posaconazole oral suspension in paediatric patients at the National Institutes of Health Clinical Center (Bethesda, MD). Methods: This retrospective single-centre study reviewed paediatric patients younger than 13 years of age initiated on posaconazole oral suspension. Patients were included if they were initiated on posaconazole for prophylaxis or treatment for fungal infections from September 2006 through March 2013 with at least one trough concentration collected after at least 7 days of therapy. Results and discussion: A total of 20 male patients were included, of whom 15 (75%) had chronic granulomatous disease. The median age of patients was 6Á5 years (range: 2Á8-10Á7). A total of 79 posaconazole trough concentrations were measured in patients receiving posaconazole as prophylaxis (n = 8) or treatment (n = 12). Posaconazole dose referenced to total body weight ranged from 10Á0 to 49Á2 mg/kg/day. Posaconazole trough concentrations ranged from undetectable (<50 ng/mL) up to 3620 ng/mL and were ≥500, ≥700 and ≥1250 ng/mL in 95%, 60% and 25% of patients, respectively. What is new and conclusions: Patients younger than 13 years of age had highly variable trough concentrations, and recommendations for the appropriate dosing of posaconazole oral suspension remain challenging. Until studies are conducted to determine the appropriate dosing of posaconazole in this patient population, therapeutic drug monitoring should be considered to ensure adequate posaconazole exposure.
SUMMARY
What is known and objective: Posaconazole is an extendedspectrum triazole antifungal with activity against a variety of clinically significant yeasts and moulds. Posaconazole is not currently approved by the U.S. Food and Drug Administration for use in children younger than 13 years of age. Our primary objective was to describe the dosing and observed trough concentrations with posaconazole oral suspension in paediatric patients at the National Institutes of Health Clinical Center (Bethesda, MD). Methods: This retrospective single-centre study reviewed paediatric patients younger than 13 years of age initiated on posaconazole oral suspension. Patients were included if they were initiated on posaconazole for prophylaxis or treatment for fungal infections from September 2006 through March 2013 with at least one trough concentration collected after at least 7 days of therapy. Results and discussion: A total of 20 male patients were included, of whom 15 (75%) had chronic granulomatous disease. The median age of patients was 6Á5 years (range: 2Á8-10Á7). A total of 79 posaconazole trough concentrations were measured in patients receiving posaconazole as prophylaxis (n = 8) or treatment (n = 12). Posaconazole dose referenced to total body weight ranged from 10Á0 to 49Á2 mg/kg/day. Posaconazole trough concentrations ranged from undetectable (<50 ng/mL) up to 3620 ng/mL and were ≥500, ≥700 and ≥1250 ng/mL in 95%, 60% and 25% of patients, respectively. What is new and conclusions: Patients younger than 13 years of age had highly variable trough concentrations, and recommendations for the appropriate dosing of posaconazole oral suspension remain challenging. Until studies are conducted to determine the appropriate dosing of posaconazole in this patient population, therapeutic drug monitoring should be considered to ensure adequate posaconazole exposure.
WHAT IS KNOWN AND OBJECTIVE
Posaconazole is an extended-spectrum triazole antifungal with potent in vitro activity against pathogenic yeasts and moulds. 1 In the United States, the oral suspension, delayed-release tablet and intravenous formulation of posaconazole are indicated for the prophylaxis of invasive Aspergillus and Candida infections in highrisk patients. In addition, the oral suspension is indicated for the treatment of oropharyngeal candidiasis including cases refractory to itraconazole or fluconazole. Posaconazole oral suspension and the delayed-release tablet are approved for patients 13 years of age and older; however, the intravenous formulation is only approved for patients 18 years of age and older. 2 As such, clinical experience and pharmacokinetic data are limited in paediatric patients younger than 13 years of age; nonetheless, posaconazole is an attractive agent for this population because of its extended spectrum of activity and favourable adverse event and drug interaction profile compared with itraconazole and voriconazole.
The use of posaconazole oral suspension can be limited by its variable oral bioavailability, even when used as approved by the U.S. Food and Drug Administration for patients 13 years of age and older. Factors that can potentially reduce the systemic exposure of posaconazole oral suspension include drug-drug interactions, increase in gastric pH, increase in gastric motility, administration in a fasted state, administration via nasogastric tube, mucositis and diarrhoea. [2] [3] [4] [5] In adults, posaconazole oral suspension exhibits linear pharmacokinetics between doses of 50-800 mg; however, saturable absorption occurs when single doses exceed 800 mg. 6 In addition to the inter-and intrapatient variability shown by posaconazole oral suspension, defining accurate target concentrations for posaconazole remains challenging. Target posaconazole concentrations greater than or equal to 700 ng/mL for prophylaxis and greater than or equal to 1000 ng/mL for treatment have been suggested.
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The primary objective of this retrospective analysis was to describe posaconazole dosing and observed trough concentrations in paediatric patients enrolled in various study protocols of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health Clinical Center (Bethesda, MD).
METHODS
This study was conducted under protocol number 09-I-N145 and was approved by the NIAID Institutional Review Board. This single-centre retrospective study included paediatric patients younger than 13 years of age initiated on posaconazole oral suspension from September 2006 through March 2013. Posaconazole trough concentrations were collected within 2 h prior to the first daily dose and after at least 7 days of therapy to ensure achievement of steady-state concentrations. Posaconazole serum concentrations were determined using a validated assay by liquid chromatography-tandem mass spectrometry assay at Mayo Medical Laboratories (Rochester, MN) 10 Demographic variables assessed included the following: age, race, sex, weight, underlying diagnosis, presence/absence of gastrointestinal (GI) disease (e.g. chronic granulomatous disease [CGD] colitis) and use of proton pump inhibitors (PPIs) or histamine H 2 -receptor antagonists (H2RAs). Patient weight, daily posaconazole dose and trough posaconazole concentration were recorded so that the dose per weight (mg/kg/day) and concentration per dose (ng/mL/mg) could be normalized. We examined the potential association with patient characteristics and the within-person average concentration. Univariate associations were examined with Wilcoxon rank-sum test for dichotomous variables and linear regression for the continuous variables of age and weight. All tests were two-sided and a P-value <0Á05 was considered significant. Analyses were performed using SAS 9Á3 (Cary, NC) and R v2Á15 (Vienna, Austria).
RESULTS
A total of 20 male patients meeting inclusion criteria were evaluated for the study. Patient demographics, underlying diagnosis and posaconazole doses and trough concentrations are included in Table 1 . There were 13 White, 5 Black and 2 Hispanic subjects. At the time of posaconazole initiation, the most common underlying diagnosis was CGD (75%) and the median age was 6Á5 years (range: 2Á8-10Á7). Posaconazole was used as primary prophylaxis in three patients, secondary prophylaxis in five patients and treatment for probable or proven invasive fungal diseases in 12 patients. All patients received posaconazole via oral administration, seven patients were taking a concomitant PPI, two patients were taking a concomitant H2RA, and eight patients had CGD colitis. Posaconazole was generally well tolerated and was not discontinued in any patient because of a suspected adverse event.
Posaconazole was dosed two to four times daily, and the dose referenced to total body weight ranged from 10 to 49Á2 mg/kg/ day. A total of 79 posaconazole trough concentrations were measured as described above. Three patients had a single concentration measured and 17 patients had multiple concentrations measured, with a median of three concentrations per patient (range: 2-12). Posaconazole trough concentrations ranged from undetectable (<50 ng/mL) up to 3620 ng/mL and were ≥500, ≥700 and ≥1250 ng/mL in 95%, 60% and 25% of patients, respectively.
The covariates assessed for an association with normalized posaconazole concentration included indication (prophylaxis/ treatment), GI disease (yes/no), use of PPI/H2RA, race (White or non-White), weight and age. Only indication and age were found to be significant. An individual's average normalized concentration (ng/mL/mg) is expected to decrease by 0Á23 (95% CI: 0Á04-0Á43) ng/mL/mg for every year increase in age (P = 0Á02).
Median within-person average concentration for those taking posaconazole as prophylaxis was 2Á34 ng/mL/mg (range: 1Á09-4Á77) compared with 0Á89 ng/mL/mg (range: 0Á56-2Á70) for those taking posaconazole for treatment of a probable or proven fungal infection (P = 0Á01). A similar analysis of the non-normalized concentration revealed no significant associations, although indication trended towards significance with a median concentration of 1114 ng/mL (range: 610-2386) in the treatment group vs. 686 ng/mL (range: 444-2160) in the prophylaxis group (P = 0Á07).
DISCUSSION
To date, only a small number of studies and case reports in patients younger than 13 years of age include both the posaconazole dose and observed concentration. A recent literature review summarized studies of posaconazole in paediatric patients 12 years of age and younger through December 2013. 11 To identify additional patients, we conducted an updated literature review of posaconazole oral suspension in paediatric patients younger than 13 years of age (see Table S1 , Online Appendix/ Supplemental Digital Content, which describes the identified publications). In our review of the literature, 10 publications were identified. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] For the indication of treatment, one prospective cohort study 12 , four case reports [13] [14] [15] [16] and one retrospective cohort study 17 described the use of posaconazole in 29 patients younger than 13 years of age using doses of 9-70 mg/kg/day. Reported posaconazole concentrations ranged from 85 to 2160 ng/mL. [12] [13] [14] [15] [16] [17] For the indication of prophylaxis, two prospective cohort studies 18, 21 and two retrospective cohort studies 19, 20 described the use of posaconazole in 53 patients younger than 13 years of age using doses of 10-21Á2 mg/kg/day. Reported posaconazole trough concentrations ranged from 104 to 3285 ng/mL in three studies [18] [19] [20] , and the fourth study 21 reported a mean trough concentration of 850 ng/mL (range not reported). Many of the published reports included small numbers of patients and did not contain details regarding concomitant medications or the amount or type of foods administered with each dose. Two additional publications, which described patients who received posaconazole oral suspension via feeding tube, were not included in our literature review because this route of administration has been shown to reduce posaconazole exposure.
2,5 The first case report described two paediatric patients with Rhizopus spp. infections after allogeneic bone marrow transplants who received high-dose posaconazole oral suspension (120-300 mg/kg/day) via nasogastric and jejunostomy tube. The first patient was a 10-year-old boy (weight: 19Á1 kg) on concomitant phenytoin, and the second patient was a 19-month-old boy (weight: 11Á6 kg). Even with high-dose therapy using divided doses, continuous administration, use of enteral nutrition and limited use of gastric acid-blocking agents, posaconazole concentrations in both patients were less than 1000 ng/mL. 22 The second case report described a 2-year-old boy (weight: 13 kg) with rhino-cerebralorbital zygomycosis receiving posaconazole oral suspension by gastrostomy tube. To obtain posaconazole concentrations >1250 ng/mL, the posaconazole dose was increased from 100 mg/dose every 6 h to 200 mg/dose every 6 h (61Á5 mg/ kg/day). 23 If posaconazole oral suspension must be administered via a feeding tube, it is recommended to closely monitor patients for breakthrough fungal infections because reduced exposure may be associated with an increased risk of treatment failure. 2 Therapeutic drug monitoring is also recommended to ensure adequate posaconazole exposure.
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In the current investigation, posaconazole trough concentrations ranged from undetectable up to 3620 ng/mL, and the weightnormalized dose ranged from 10Á0 to 49Á2 mg/kg/day. An argument could be made that the variability in posaconazole concentrations would be expected with such a wide range of doses; however, variable oral bioavailability has been established with posaconazole oral suspension. 4, 7 In addition, three of the cohort studies identified in the paediatric literature review reported a significant variability in posaconazole concentrations when using a standardized posaconazole dose based on body weight or body surface area. [19] [20] [21] Posaconazole oral suspension should always be given with, or immediately after food or a nutritional supplement to maximize oral bioavailability. If concentrations are found to be subtherapeutic, a review of the patient's dietary intake should be performed and high-fat items could be used. Other strategies that can be used include further dividing the daily dose or administration with an acidic beverage. 24, 25 Although PPIs and H2RAs did not significantly decrease posaconazole concentrations in our study, when administered with concomitant posaconazole oral suspension, these two classes of medications have been shown to lower posaconazole exposure. 2, 24, 25 Therefore, avoidance of these agents in the setting of suboptimal posaconazole concentrations is still recommended.
Potential limitations to our study include its retrospective nature and relatively small sample size which consisted primarily of male CGD patients; therefore, our results cannot necessarily be extrapolated to other patient populations. In addition, adherence for outpatients and timing of posaconazole administration with regard to meals was not recorded. Outcomes were not reported because many of our patients receive care at other institutions and full histories are not always available. In addition, interpreting the exact role of posaconazole in patient outcomes is limited by concurrent or sequential treatment with other antifungal agents and, in some patients, adjunctive surgical debridement or granulocyte transfusion. Moreover, there may be additional variables, not identified in this investigation, which may have influenced posaconazole disposition and subsequent concentrations. Nevertheless, our data reflect the use of posaconazole oral suspension in a unique patient population.
WHAT IS NEW AND CONCLUSION
In conclusion, we found a wide range of dosing and high interand intrapatient variability in posaconazole concentrations, which make it difficult to determine the optimal dose and frequency in patients younger than 13 years of age. Based on our findings and the published literature, there may not be a predictable approach for a dose-concentration correlation. Before implementing therapy with posaconazole oral suspension in paediatric patients, the following factors should be reviewed: (1) route of administration; (2) patient's ability to take the drug with meals, liquid nutritional supplement or an acidic carbonated beverage; (3) the number of daily posaconazole doses; and (4) concomitant medications that can decrease posaconazole exposure. Therapeutic drug monitoring can be used to assess posaconazole adherence and verify adequate drug exposure; this approach serves to maximize the potential for therapeutic success, particularly in the treatment for invasive fungal diseases.
Further pharmacokinetic studies of posaconazole in diverse patient populations are needed to optimize its use, especially in paediatric patients younger than 13 years of age. Compared with the oral suspension, the posaconazole delayed-release tablet has an improved pharmacokinetic profile including greater oral bioavailability and less frequent dosing. 2, 3 Unfortunately, the posaconazole delayed-release tablet is not approved for use in children younger than 13 years of age. Age notwithstanding, some patients may have difficulty swallowing the delayedrelease tablet, which is an important consideration, as they cannot be crushed or divided. 2 In addition, alternative dosing strategies in paediatric patients using body surface area or a new formulation of posaconazole oral suspension with improved oral bioavailability similar to the delayed-release tablet should be considered.
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